## APOPC Asia Pacific Oncology Pharmacy Congress 2024 (APOPC 2024)

Best Poster Award			
P-13	Chatchanin Ajalanond	Phramongkutklao Hospital	The study of pharmacotherapeutic strategies for cancer cachexia in advanced solid malignancy in Thailand
Poster Award			
P-02	Dang Chee Chean	Hospital Melaka	Novel Therapeutic Effects and Mechanisms of Polo-like kinase 4 Inhibition in TP53- Mutated Acute Myeloid Leukaemia
P-11	Yovita Diane Titiesari	MRCCC Siloam Hospitals Semanggi Jakarta	Enhancing Medication Safety for Oncology Patients: The Essential Role of Clinical Pharmacist in Medication Reconciliation
P-14	Yasutaka Sakamoto	Yokohama City University Hospital	Nausea and Vomiting Induced by 10-min and 60-min Dosing of Bendamustine in Patients with B-cell non-Hodgkin Lymphoma in Japan, A Single Center Retrospective Study
P-15	Chew Lita	National Cancer Centre Singapore	Integrating artificial intelligence into the development of a chemotherapy wastage calculator
P-16	Keary Rui Zhou	The Chinese University of Hong Kong	Immune-Related Adverse Events of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer Patients Concomitantly Treated with Systemic Therapy: A Retrospective Study in a Hong Kong Hospital
P-18	Sukmin Hong	Seoul National University Hospital	The Role of Pharmacists in Managing Pneumocystis jirovecii Pneumonia Prophylaxis in Pediatric Patients with Acute Lymphoblastic Leukemia
P-20	Koji Hashiguchi	Yokohama Minami Kyosai Hospital	Retrospective Analysis of Mohs Paste Use in Patients with Skin Metastases at Yokohama Minami Kyosai Hospital
P-23	Seiji Miyaura	Miyagi Cancer Center	Perioperative Methotrexate Management and Postoperative Infection in Non- Orthopedic Surgeries: A Study from Miyagi Cancer Center
P-24	Minoh Ko	Seoul National University	Optimizing Medication Use in Terminal Cancer Patients: A Pharmacist-led Deprescribing Approach in Consultation-based Palliative Care Team
P-26	Mayu Suzukawa	Keio University Graduate School of Pharmaceutical Sciences	Preventive Effects of Non-Sedating Antihistamines Premedication on Subcutaneous Daratumumab-Associated Infusion-Related Reactions: A Prospective Cohort Study